Bausch Health Announces Third Quarter 2026 Results, Raises Guidance

October 28, 2026

- **Third Quarter Consolidated Revenues of $2.94 billion, up 10% on a Reported basis and 8% on an Organic[1] basis over the prior year period**
- **GAAP Net Income Attributable to Bausch Health of $436 million and GAAP Net Income of $446 million**
- **GAAP Earnings per Diluted Share Attributable to Bausch Health of $1.15 compared to $0.48 in the prior year period; Adjusted Earnings per Diluted Share[1] of $1.77 compared to $1.16 in the prior year period, an increase of 53%**
- **Consolidated Adjusted EBITDA Attributable to Bausch Health[1] of $1,305 million, up 32% over the prior year period**

BAUSCH HEALTH EXCLUDING BAUSCH + LOMB THIRD QUARTER 2026 RESULTS

- **Delivered fourteenth consecutive quarter of year-over-year Revenue and Adjusted EBITDA[1] growth, with 12% Reported and 8% Organic Revenue[1] growth and 32% Adjusted EBITDA[1] growth**
- **Net Income increased $205 million over the prior year**
- **Generated $581 million in Cash Provided by Operating Activities and $539 million in Adjusted Cash Flows from Operations[1]**
- **Raising full year 2026 Revenue, Adjusted EBITDA[1], and Adjusted Cash Flows from Operations[1] guidance**

LAVAL, QC, October 28, 2026 – Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its third quarter 2026 financial results and other key updates from the quarter.

"Bausch Health, excluding Bausch + Lomb, delivered another solid quarter, marking fourteen consecutive quarters of year-over-year Revenue and Adjusted EBITDA growth. We also achieved an important milestone, with quarterly Adjusted EBITDA, excluding Bausch + Lomb, exceeding $1 billion for the first time. Our performance reflects disciplined execution across the portfolio, with healthy cash generation supporting more than $500 million of net debt reduction during the quarter. These results give us confidence to again raise our full year 2026 guidance. We remain focused on operational excellence, sustainable growth, and long-term value creation," said Thomas J. Appio, Chief Executive Officer, Bausch Health.

The Company also announced that its Board of Directors has authorized a $50 million share repurchase program, with the primary objective of offsetting dilution associated with the anticipated vesting of management equity awards in 2027.

Third Quarter 2026 Revenue Performance

Total consolidated reported revenues were $2.94 billion for the third quarter of 2026, compared with $2.68 billion in the third quarter of 2025, an increase of $260 million, or 10%. Excluding the impact of acquisitions of $37 million and divestitures and discontinuations of $11 million, revenue increased 8% on an organic[1] basis compared with the third quarter of 2025. The net impact of foreign exchange was de minimis in the quarter.

[1] This is a non-GAAP measure or a non-GAAP ratio. For further information on non-GAAP measures and non-GAAP ratios, please refer to the "Non-GAAP Information" section of this news release. Please also refer to tables at the end of this news release for a reconciliation of this and other non-GAAP measures and ratios to the most directly comparable GAAP measure.

Read More

View original release here:
https://www.prnewswire.com/news-releases/bausch-health-announces-third-quarter-2026-results-raises-guidance-302922662.html?tc=eml_cleartime

Investor Inquiries
ir@bauschhealth.com
877-281-6642
514-856-3855 (Canada)

Media inquiries
Corporate.communications@bauschhealth.com
848-264-0934

LEGAL NOTICE PRIVACY POLICY

EMAIL ALERTS EMAIL PAGE RSS FEED

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.
©2026 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION

Powered by SITECORE